에서 실시간으로 운영 중이에요! 자세히 알아보기

Pliant Therapeutics

PLRX

시가총액 US$5572만

0.8999 USD

-0.0725

7.46%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

0.9240

+0.0241

2.68%

1일

-7.46%

5일

-12.63%

1개월

-15.9%

3개월

-18.93%

6개월

-30.78%

연초 이후

-28.01%

1년

-45.46%

5년

-94.65%

10년

-95.78%

소개: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

직원 수: 49

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 100%

부정적 0%

중립

GlobeNewsWire

16일 전

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise

중립

GlobeNewsWire

2개월 전

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).

$Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors$

중립

GlobeNewsWire

2개월 전

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.

중립

GlobeNewsWire

3개월 전

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise

중립

Seeking Alpha

4개월 전

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

중립

GlobeNewsWire

4개월 전

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.

중립

GlobeNewsWire

5개월 전

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors

중립

GlobeNewsWire

5개월 전

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D., Pliant's Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.

중립

GlobeNewsWire

5개월 전

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.

$Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors$

중립

GlobeNewsWire

6개월 전

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months

$Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting$

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.

Pliant Therapeutics PLRX 시가총액 US$5572만

뉴스

Pliant Therapeutics

PLRX

시가총액 US$5572만